Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03753581
Other study ID # EUEYF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 31, 2018
Est. completion date June 10, 2021

Study information

Verified date November 2018
Source University of Castilla-La Mancha
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect on the healing of pressure ulcers in elderly people using a care protocol plus the application of microcurrent patches during 12 hours per day compared to the effect of the same protocol plus placebo electric stimulation.


Description:

The design of this study is a multicentric, parallel, randomised, triple blind clinical trial with placebo control. The size of the sample will be 30 participants older than 60 years old who are institutionalized in some nursing homes in Spain.They will be randomized in two groups: control or experimental. The variables of the study will be collected at three time points: before the intervention, 14 days after the start of the intervention and at the end of the intervention. The statistical analysis will be an intention-to-treat analysis. For the main outcomes variables a two-factor ANOVA will-be performed (intervention-time) with a post-hoc analysis with Bonferroni correction


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 10, 2021
Est. primary completion date June 10, 2021
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Adults over 60 institutionalized in nursing homes. - Participants presenting pressure ulcers in phase II, III and IV according to the North American National Pressure Ulcer Advisory Panel System and the European Pressure Ulcer Advisory Panel System. - Time of evolution of the pressure ulcer greater than 1 month and less than 24 months. - Ulcer size greater than 1 cm2. - Less than 14 points on the Braden scale. Exclusion Criteria: - Presence of a pacemaker or any implanted electrical device. - Metal implants in the pressure ulcer area. - Pressure ulcer in occipital area. - Cancer. - Osteomyelitis. - 3 or more abnormal blood values at the beginning of the study that indicate a limited healing potential (anemia, iron deficiency, protein deficiency, dehydration, uncontrolled diabetes or hypothyroidism) - Allergies to the usual cures protocol established. - Systemic infection - Recent history (minimum of 30 days) of treatment with growth factors or vacuum-assisted treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Care protocol plus microcurrents
CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service. MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42µA with a current density of 4.2 µA.
Care protocol plus placebo microcurrents
The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents

Locations

Country Name City State
Spain Juan Avendaño-Coy Toledo

Sponsors (3)

Lead Sponsor Collaborator
University of Castilla-La Mancha Residencia de Mayores Río Tajo ARTEVIDA. Centro Serviger Talavera, Residencia Geriátrica San Diego, S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Effectiveness of blinding The participants, evaluators and those who apply the intervention will be asked if they know the research group to which the study subject belongs. At 14 days after the start of the intervention
Primary Ulcer healing 1 day before the intervention start It will be evaluated with the Pressure Ulcer Scale for Healing (PUSH). It was developed by the National Pressure Ulcer Advisory Panel (NPUAP) to monitor the change in the status of pressure ulcers over time.
The ulcer is categorized according to the surface area, exudate and type of wound tissue. A partial score is recorded for each of these ulcer characteristics:
Surface area (in cm2): 10 points (0 points=0 cm2; 10 points= >24 cm2)
Exudate amount: 3 points (0 points= none; 3 points=heavy).
Tissue type: 4 points (0 points= closed; 4 points= necrotic tissue).
To obtain the total score, the sub-scores are added. The minimum score is 0, which means that the ulcer is healed and the maximum score is 17, which means that the ulcer surface is greater than 24 cm2, that there is a heavy exudate and necrotic tissue.
A comparison of total scores measured over time provides an indication of the improvement or deterioration in pressure ulcer healing.
1 day before the start of the intervention
Primary Ulcer healing at 14 days It will be evaluated with the Pressure Ulcer Scale for Healing (PUSH). It was developed by the National Pressure Ulcer Advisory Panel (NPUAP) to monitor the change in the status of pressure ulcers over time.
The ulcer is categorized according to the surface area, exudate and type of wound tissue. A partial score is recorded for each of these ulcer characteristics:
Surface area (in cm2): 10 points (0 points=0 cm2; 10 points= >24 cm2)
Exudate amount: 3 points (0 points= none; 3 points=heavy).
Tissue type: 4 points (0 points= closed; 4 points= necrotic tissue).
To obtain the total score, the sub-scores are added. The minimum score is 0, which means that the ulcer is healed and the maximum score is 17, which means that the ulcer surface is greater than 24 cm2, that there is a heavy exudate and necrotic tissue.
A comparison of total scores measured over time provides an indication of the improvement or deterioration in pressure ulcer healing.
At 14 days after the start of the intervention
Primary Ulcer healing at 26 days It will be evaluated with the Pressure Ulcer Scale for Healing (PUSH). It was developed by the National Pressure Ulcer Advisory Panel (NPUAP) to monitor the change in the status of pressure ulcers over time.
The ulcer is categorized according to the surface area, exudate and type of wound tissue. A partial score is recorded for each of these ulcer characteristics:
Surface area (in cm2): 10 points (0 points=0 cm2; 10 points= >24 cm2)
Exudate amount: 3 points (0 points= none; 3 points=heavy).
Tissue type: 4 points (0 points= closed; 4 points= necrotic tissue).
To obtain the total score, the sub-scores are added. The minimum score is 0, which means that the ulcer is healed and the maximum score is 17, which means that the ulcer surface is greater than 24 cm2, that there is a heavy exudate and necrotic tissue.
A comparison of total scores measured over time provides an indication of the improvement or deterioration in pressure ulcer healing.
At 26 days after the start of the intervention
Secondary Stage of pressure ulcer 1 day before the intervention start According to the North American National Pressure Ulcer Advisory Panel System and the European Pressure Ulcer Advisory Panel System 1 day before the start of the intervention
Secondary Stage of pressure ulcer at 14 days According to the North American National Pressure Ulcer Advisory Panel System and the European Pressure Ulcer Advisory Panel System At 14 days after the start of the intervention
Secondary Stage of pressure ulcer at 26 days According to the North American National Pressure Ulcer Advisory Panel System and the European Pressure Ulcer Advisory Panel System At 26 days after the start of the intervention
Secondary Ulcer depth 1 day before the intervention start It will be registered in mm with a Swab, specimen collection. Deltalab, SL 1 day before the start of the intervention
Secondary Ulcer depth at 14 days It will be registered in mm with a Swab, specimen collection. Deltalab, SL At 14 days after the start of the intervention
Secondary Ulcer depth at 26 days It will be registered in mm with a Swab, specimen collection. Deltalab, SL At 26 days after the start of the intervention
Secondary Ulcer área 1 day before the intervention start It will be registered in cm2 with the application for pressure ulcer management Mobile Wound Analyzer (MOWA) for IOS Version 1.7.2011. Developer: Bello Ciro (Italy) 1 day before the start of the intervention
Secondary Ulcer área at 14 days It will be registered in cm2 with the application for pressure ulcer management Mobile Wound Analyzer (MOWA) for IOS Version 1.7.2011. Developer: Bello Ciro (Italy) At 14 days after the start of the intervention
Secondary Ulcer área at 26 days It will be registered in cm2 with the application for pressure ulcer management Mobile Wound Analyzer (MOWA) for IOS Version 1.7.2011. Developer: Bello Ciro (Italy) At 26 days after the start of the intervention
Secondary Cutaneous blood flow in the area surrounding the pressure ulcer 1 day before the intervention start It will be recorded in the greater side of the ulcer by cutaneous doppler laser flowmetry with a scale of 0-1000 units (model DRT4, Moor instruments, Devon, UK) 1 day before the start of the intervention
Secondary Cutaneous blood flow in the area surrounding the pressure ulcer at 14 days It will be recorded in the greater side of the ulcer by cutaneous doppler laser flowmetry with a scale of 0-1000 units (model DRT4, Moor instruments, Devon, UK) At 14 days after the start of the intervention
Secondary Cutaneous blood flow in the area surrounding the pressure ulcer at 26 days It will be recorded in the greater side of the ulcer by cutaneous doppler laser flowmetry with a scale of 0-1000 units (model DRT4, Moor instruments, Devon, UK) At 26 days after the start of the intervention
Secondary Pain caused by pressure ulcer 1 day before the intervention start: numerical scale It will be assessed with the numerical scale of the pain that includes the values from 0 (absence of pain) to 10 (maximum pain) 1 day before the start of the intervention
Secondary Pain caused by pressure ulcer at 14 days: numerical scale It will be assessed with the numerical scale of the pain that includes the values from 0 (absence of pain) to 10 (maximum pain) At 14 days after the start of the intervention
Secondary Pain caused by pressure ulcer at 26 days: numerical scale It will be assessed with the numerical scale of the pain that includes the values from 0 (absence of pain) to 10 (maximum pain) At 26 days after the start of the intervention
Secondary Administration of analgesic drugs 1 day before the intervention start The type of analgesic will be registered according to WHO therapeutic steps 1 day before the start of the intervention
Secondary Administration of analgesic drugs at 14 days The type of analgesic will be registered according to WHO therapeutic steps At 14 days after the start of the intervention
Secondary Administration of analgesic drugs at 26 days The type of analgesic will be registered according to WHO therapeutic steps At 26 days after the start of the intervention
Secondary Exudate culture of the ulcer 1 day before the intervention start The presence of infection in the ulcer will be evaluated with a exudate culture 1 day before the start of the intervention
Secondary Exudate culture of the ulcer at 14 days The presence of infection in the ulcer will be evaluated with a exudate culture At 14 days after the start of the intervention
Secondary Exudate culture of the ulcer at 26 days The presence of infection in the ulcer will be evaluated with a exudate culture At 26 days after the start of the intervention
Secondary Administration of systemic antibiotics 1 day before the intervention start The administration of antibiotics will be recorded 1 day before the start of the intervention
Secondary Administration of systemic antibiotics at 14 days The administration of antibiotics will be recorded At 14 days after the start of the intervention
Secondary Administration of systemic antibiotics at 26 days The administration of antibiotics will be recorded At 26 days after the start of the intervention
Secondary Blood pressure 1 day before the intervention start The systolic and diastolic blood pressure will be recorded in mm/Hg with a tensiometer. It will be taken at rest, making 2 measurements separated by a 1-2 minute interval 1 day before the start of the intervention
Secondary Blood pressure at 14 days The systolic and diastolic blood pressure will be recorded in mm/Hg with a tensiometer. It will be taken at rest, making 2 measurements separated by a 1-2 minute interval At 14 days after the start of the intervention
Secondary Blood pressure at 26 days The systolic and diastolic blood pressure will be recorded in mm/Hg with a tensiometer. It will be taken at rest, making 2 measurements separated by a 1-2 minute interval At 26 days after the start of the intervention
Secondary Capillary blood glucose 1 day before the intervention start It will be recorded in mg/dl with a glucometer, taking as a glycemia value the average of 2 measurements with an interval of 24 hours between each record 1 day before the start of the intervention
Secondary Capillary blood glucose at 14 days It will be recorded in mg/dl with a glucometer, taking as a glycemia value the average of 2 measurements with an interval of 24 hours between each record At 14 days after the start of the intervention
Secondary Capillary blood glucose at 26 days It will be recorded in mg/dl with a glucometer, taking as a glycemia value the average of 2 measurements with an interval of 24 hours between each record At 26 days after the start of the intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04159012 - NESBID: Neuro-Stimulation of the Brain in Depression N/A
Recruiting NCT05968274 - The Effect of Rebox Current in Pain Management Phase 4
Recruiting NCT04914975 - The Effect of NMES on Bowel Management in People With Chronic SCI N/A
Recruiting NCT05971030 - Clinical Exploratory Research of Medial Prefrontal Cortex Combined With Dorsolateral Prefrontal Cortex Electrical Stimulation in the Treatment of Alzheimer's Disease N/A
Completed NCT02406339 - Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's N/A
Completed NCT03796117 - Pulsed Current Versus Russian Current Effects in Healthy Young Subjects. N/A
Recruiting NCT00739362 - Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment Phase 2
Completed NCT03467087 - Safety and Feasibility of Electrical Muscle Stimulation During Stem Cell Transplantation or Intensive Chemotherapy N/A
Active, not recruiting NCT04276077 - Electrical Muscle Stimulation on Muscle Stiffness and Functional Capacity in Post-menopausal Women N/A
Completed NCT03319095 - Intravaginal Electrical Nerve Stimulation in Women With Non-contracting Pelvic Floor N/A
Recruiting NCT04036630 - Enhancing Speech Intelligibility Using Transcranial Alternating Current Stimulation (tACS) N/A
Completed NCT03151889 - Eletric Stimulation for Hipossalivation Induced by Radiotherapy N/A
Completed NCT04076878 - Effects of Using the Electrodress Mollii on Spasticity N/A
Active, not recruiting NCT01162993 - Effect of Spinal Cord Stimulation (SCS) in Painful Diabetic Polyneuropathy N/A